New writeup out now! This time, I cover a stable & profitable Japanese net-net with a 150% of market cap covered by cash & securities. I expect profitability to improve from here, driving returns. TSE reforms are the cherry on top! 🇯🇵
Link in comments/bio
$5592.T operates Japan’s 🇯🇵 largest pharmacy reservation platform.
• 34% EBIT CAGR
• Network effects
• Recurring revenue & high margins
• Hikari Tsushin owns 40%
• Proven management team
Trading at a 40% discount to peers likely due to forced selling.
Link in bio
$5592.T operates Japan’s 🇯🇵 largest pharmacy reservation platform.
• 34% EBIT CAGR
• Network effects
• Recurring revenue & high margins
• Hikari Tsushin owns 40%
• Proven management team
Trading at a 40% discount to peers likely due to forced selling.
Link in bio
$5592.T operates Japan’s 🇯🇵 largest pharmacy reservation platform.
• 34% EBIT CAGR
• Network effects
• Recurring revenue & high margins
• Hikari Tsushin owns 40%
• Proven management team
Trading at a 40% discount to peers likely due to forced selling.
Link in bio
@Tintincapital@rhomboid1MF For most documents I use https://t.co/NCIYjFNXqp suggested by @AltayCapital usually this is good enough and much better with tables and images than google translate. If it’s not good, I then go for LLMs as they are very good as long as you feed it one page or screenshot at a time
After a year-long hiatus, I’ll publish a new deep dive tommorow!
This stock came up on my Magic Formula screener recently. High growth, recurring revenue, network effects & favourable macro tailwinds.
@InvestInJapan One of my favourite authors here has written a 2-pager on it.
By far my laziest idea. Some reasons I thought this Jocky bet $5592.JP was interesting 🧵
- Network Effects
- Scale Benefits
- Shareholder value+ IRR Focus
- Disciplined M&A for Healthcare Software = Potential $CSU like strategy?
- 20%+ Earnings growth projected but this could be sandbagging ??
@and_valleys@Mr_Neutral_Man Lower leverage provides balance sheet capacity that can be deployed during market dislocations, creating potential upside not reflected in current earnings.
@MontvilleCap@IggyOnInvesting Honestly, I just dont think they are the buyback type unfortunately. When it comes to capital allocation, none of their explanations sound genuine to me.